Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label topical VDA-1102 study with within-patient vehicle control in adults with relapsed stage 1 mycosis fungoides
MOH_2021-01-20_009688Phase 2Not yet recruiting
- Sponsor
- Vidac Pharma
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tuvatexib in mycosis fungoides (MF), sponsored by Vidac Pharma. Primary endpoints: Efficacy of topical VDA-1102 and Safety and tolerability of topical VDA-1102. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
tuvatexib
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on MOH_2021-01-20_009688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-20_009688.